Detection of prostate cancer in the PSA gray zone using prostate-specific antigen mass ratio combined with PI-RADS score

Background: The study aimed to assess the diagnostic performance of prostate-specific antigen mass ratio (PSAMR) in combination with the Prostate Imaging Reporting and Data System (PI-RADS) score for detecting prostate cancer (PCa) in patients presenting with mildly elevated prostate-specific antigen (PSA) levels (4–10 ng/mL). Methods: A retrospective analysis was conducted involving 208 patients with PSA levels between 4 and 10 ng/mL who underwent multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound-guided transperineal prostate biopsy. PSA-derived parameters and PI-RADS scores were incorporated into logistic regression models to predict the presence of PCa. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Additionally, Spearman’s correlation analysis was performed to determine the relationship between each parameter and the prediction model with disease severity ratings. Results: Of the 208 patients, PCa was confirmed by biopsy in 62 cases. The combination of PSAMR and PI-RADS score yielded an area under the ROC curve (AUC) of 0.874 (95% confidence interval (CI): 0.821–0.916, p < 0.001), which was higher than the AUCs for PSAMR or PI-RADS score alone, indicating superior diagnostic accuracy. Correlation analysis also revealed that the combined model had the strongest association with disease severity. The order of correlation coefficients was as follows: PSAMR combined with PI-RADS score (Model A) > Prostate-specific antigen density (PSAD) combined with PI-RADS score (Model B) > PI-RADS score alone > PSAMR alone > PSAD alone. Conclusions: The combination of PSAMR and PI-RADS score significantly enhances the accuracy of PCa detection in patients with PSA levels of 4–10 ng/mL. This approach may contribute to more effective screening strategies while minimizing unnecessary biopsies. Furthermore, given their positive correlation with disease severity, PSAMR and PI-RADS scores together may also assist in predicting PCa progression risk.

Prostate cancer; Prostate specific antigen; Magnetic resonance imaging; PI-RADS; PSAMR

[1] Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025; 333: 1433–1446.

[2] Li M, Hu M, Jiang L, Pei J, Zhu C. Trends in cancer incidence and potential associated factors in China. JAMA Network. 2024; 7: e2440381.

[3] D’Amico AV. PSA screening and prostate cancer mortality. JAMA. 2024; 332: 842–843.

[4] McLaughlin PW, Cousins MM, Tsodikov A, Soni PD, Crook JM. Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. Scientific Reports. 2024; 14: 5810.

[5] Pinsky PF, Parnes H. Screening for prostate cancer. The New England Journal of Medicine. 2023; 388: 1405–1414.

[6] de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group. A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer. European Urology. 2023; 84: 426–434.

[7] Vickers A, O’Brien F, Montorsi F, Galvin D, Bratt O, Carlsson S, et al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. The BMJ. 2023; 381: e071082.

[8] Choi HC, Park JH, Cho BL, Son KY, Kwon HT. Prostate specific antigen mass ratio potential as a. prostate cancer screening tool. Journal of Urology. 2010; 184: 488–493.

[9] Park JH, Cho BL, Kwon HT, Lee CM, Han HJ. Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population. Journal of Urology. 2009; 182: 106–110; discussion 110–111.

[10] Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. European Radiology. 2012; 22: 746–757.

[11] Barrett T, Rajesh A, Rosenkrantz AB, Choyke PL, Turkbey B. PI-RADS version 2.1: one small step for prostate MRI. Clinical Radiology. 2019; 74: 841–852.

[12] Guo E, Xu L, Zhang D, Zhang J, Zhang X, Bai X, et al. Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL: a systematic review and meta-analysis. Insights into Imaging. 2024; 15: 147.

[13] Fukui Y, Yamada Y, Sakamoto S, Horikoshi T, Zhao X, Sato K, et al. Preoperative PI-RADS v2.1. scoring system improves risk classification in patients undergoing radical prostatectomy. Anticancer Research. 2023; 43: 5705–5712.

[14] Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, et al. PI-RADS steering committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology. 2019; 292: 464–474.

[15] Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncology. 2024; 10: 745–754.

[16] Park SY, Jung DC, Oh YT, Cho NH, Choi YD, Rha KH, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016; 280: 108–116.

[17] Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. The American Journal of Surgical Pathology. 2016; 40: 244–252.

[18] Pinsky PF. Prostate biopsy in men with an elevated PSA level—reducing overdiagnosis. The New England Journal of Medicine. 2024; 391: 1153–1154.

[19] Li D, Zhang L, Xu Y, Wu X, Hua S, Jiang Y, et al. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model. Journal of Cancer Research and Clinical Oncology. 2023; 149: 11309–11317.

[20] Hong SK, Oh JJ, Byun SS, Hwang SI, Choo MS, Lee SE. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL. BJU International. 2012; 110: E81–E85.

[21] Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of prostate imaging reporting and data system version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European Radiology. 2017; 27: 5204–5214.

[22] Woo S, Kim SY, Lee J, Kim SH, Cho JY. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer. European Radiology. 2016; 26: 3580–3587.

[23] Liu C, Liu SL, Wang ZX, Yu K, Feng CX, Ke Z, et al. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment. Asian Journal of Andrology. 2018; 20: 459–464.

[24] Crulhas BP, Basso CR, Castro GR, Pedrosa VA. Detection of prostate cancer biomarker PCA3 by using Aptasensors. Current Medicinal Chemistry. 2022; 29: 5895–5902.

[25] Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine. 2022; 60: 1261–1277.